2024-04-10 08:24:27 ET
DENVER, Colo., Apr 10, 2024 ( 247marketnews.com )- Clearmind Medicine Inc. (NASDAQ: CMND ) filed a patent application with United States Patent and Trademark Office for the use of 3-methylmethcathinone to prevent and/or treat eating disorders either alone or in conjunction with Palmitoylethanolamide.
“The field of weight loss has been a blockbuster of the pharmaceutical industry and generates billions of dollars to companies who are active in this space. We at Clearmind have made it our goal to be at the forefront of developments in fields where we believe that we have an advantage over the marketed treatments, with weight loss being one of them. With sort in supply, shortage of active ingredients, high price, adverse events and inconvenient method of administration, we believe that our molecules may have the potential over the ones already available “
The post Clearmind Medicine Applies for Psychedelic-Based Eating Disorder Treatment Patent appeared first on 24/7 MarketNews .
For further details see:
Clearmind Medicine Applies for Psychedelic-Based Eating Disorder Treatment Patent